Abstract: The present invention provides a virus-like particle comprising several or more types of HBs-L antigen proteins or a virus-like particle composition comprising a combination of the virus-like particles, for the purpose of provision of an antigen that triggers an immune reaction against HBV of various genotypes.
Abstract: The present invention provides a virus-like particle comprising several or more types of HBs-L antigen proteins or a virus-like particle composition comprising a combination of the virus-like particles, for the purpose of provision of an antigen that triggers an immune reaction against HBV of various genotypes.
Abstract: An object of the present invention is to provide an immunoassay that has excellent detection sensitivity and that remarkably suppresses the detection background. The means for achieving the object is to provide a virus-like particle that contains a protein having self-organization ability, the particle being modified with a biologically active molecule at at least one cysteine residue of the protein having self-organization ability via a thiol group or thiol groups thereof.
Abstract: The invention provides a therapeutic drug that uses hollow protein nanoparticles displaying an antibody against a specific cell or specific tissue. The effectiveness of the drug has been proved by animal testing. The invention also provides a therapeutic method using such a drug. In a drug according to the present invention, a substance to be transferred into a cell for treating a disease (for example, a cancer treating gene such as a thymidine kinase gene derived from simple herpes virus) is encapsulated in hollow nanoparticles of a particle-forming protein (for example, hepatitis B virus surface-antigen protein that has been modified to lack its infectivity to hepatocytes and display an antibody). The particle surface of the drug displays an antibody, such as a cancer specific antibody, that recognizes an antigen molecule displayed on the surface of a specific cancer cell.
Type:
Grant
Filed:
March 26, 2003
Date of Patent:
May 31, 2011
Assignees:
Japan Science and Technology Agency, Beacle, Inc.
Abstract: As a versatile means for specifically and safely transporting and transferring substances (genes, proteins, compounds, etc.) into target cells and tissues, hollow nano particles comprising a protein capable of forming particles (e.g., hepatitis B virus surface antigen protein), and a biorecognition molecule introduced therein, are provided.
Abstract: The present invention relates to a method of producing a composite particle of a nanoparticle and a liposome in which a substance to be introduced has been encapsulated, characterized in that a hollow nanoparticle containing a hepatitis B virus protein or a modification thereof is fused to the liposome in which the substance to be introduced has been encapsulated.
Type:
Application
Filed:
September 1, 2006
Publication date:
March 15, 2007
Applicants:
Japan Science and Technology Agency, Osaka University, Beacle Inc.
Inventors:
Shun-ichi Kuroda, Atsuko Ueda, Mana Nagita